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Abstract
Background:  Leber's hereditary optic neuropathy (LHON) and autosomal dominant optic
atrophy (ADOA) are the most frequent forms of hereditary optic neuropathies. LHON is
associated with mitochondrial DNA (mtDNA) mutations whereas ADOA is mainly due to
mutations in the OPA1 gene that encodes a mitochondrial protein involved in the mitochondrial
inner membrane remodeling. A striking influence of mtDNA haplogroup J on LHON expression
has been demonstrated and it has been recently suggested that this haplogroup could also influence
ADOA expression. In this study, we have tested the influence of mtDNA backgrounds on OPA1
mutations.
Methods: To define the relationships between OPA1 mutations and mtDNA backgrounds, we
determined the haplogroup affiliation of 41 French patients affected by OPA1-related ADOA by
control-region sequencing and RFLP survey of their mtDNAs.
Results:  The comparison between patient and reference populations did not revealed any
significant difference.
Conclusion: Our results argue against a strong influence of mtDNA background on ADOA
expression. These data allow to conclude that OPA1 could be considered as a "severe mutation",
directly responsible of the optic atrophy, whereas OPA1-negative ADOA and LHON mutations
need an external factor(s) to express the pathology (i.e. synergistic interaction with mitochondrial
background).
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Background
Hereditary optic atrophies are frequently related to mito-
chondrial dysfunction. The maternally-transmitted
Leber's hereditary optic neuropathy (MIM535000) is
associated with one the three main primary point muta-
tions of the mitochondrial genome. With incomplete pen-
etrance, theses mutations induce, between 15 and 35
years old, an acute and bilateral loss of visual acuity with
a caecocentral scotoma and a dyschromatopsy. A "sister
disease" of LHON, autosomal dominant optic atrophy
(MIM #165500) is the second most common form of
inherited optic neuropathy, with a frequency of 1:12 000
to 1:50 000 [1,2] This disease is characterized by an insid-
ious onset of bilateral visual impairment in early child-
hood with moderate to severe loss of visual acuity,
temporal optic disc pallor, abnormalities of color vision,
and caecocentral visual field scotoma. Electrophysiologi-
cal and histopathological studies have suggested that the
underlying defect is the retinal ganglion cell (RGC) degen-
eration leading to atrophy of the optic nerve. Until now,
four loci have been designated for ADOA [2]. Among
these, the most commonly mutated gene is OPA1 (3q28–
29) [3,4]. One hundred and seventeen OPA1 gene muta-
tions, mainly family-specific [5], were described with sub-
stitutions, deletions and insertions respectively spread
throughout the coding sequence of the gene. Most are
localized in the GTPase domain and the N-terminus of the
protein, whereas the C-terminus is largely spared.
The mitochondrial genetic background is known to influ-
ence the expression of LHON [6] since mitochondrial pri-
mary mutations G11778A and T14484C showed
significant clustering on Caucasian mtDNA haplogroup J.
Haplogroup J was also found to be three-fold over-repre-
sented in patients with ADOA not related to OPA1 muta-
tions [7].
In order to test the influence of the mitochondrial genetic
background on the penetrance of the mutations of the
OPA1 gene, we compared the distribution of mtDNA hap-
logroups between 41 French patients and 1385 individu-
als of the French population described by Richard and al.
[8].
Methods
Patients
Screening for ADOA French patients carrying OPA1 muta-
tions was done by the Department of Biochemistry and
genetics in the University Hospital of Angers. Genetic
analyses were carried out with the appropriate consent of
the patients and in compliance with the Helsinki Declara-
tion. Experimental research have been performed with the
ethics approval of the " centre hospitalier universitaire
d'Angers" and ethics policy of the French mitochondrial
disease network [9]. This laboratory collect samples from
all French patients suspected to be affected by ADOA. All
the patients presented typical history of ADOA with insid-
ious, painless and progressive bilateral visual loss, impair-
ment of visual acuity, central scotoma and optic nerve
pallor. OPA1 analysis was carried out by sequencing with
the appropriate consent of the patients. Among the cohort
of individuals diagnosed as carriers of the OPA1 muta-
tions, we have listed 41 distinct maternal lineages.
Analysis of the haplogroups
Each patient's DNA was extracted from blood using stand-
ard procedures (phenol/chloroform or Qiagene® QIAAmp
DNA kit). For each patient, the mitochondrial DNA con-
trol region was then amplified using the following prim-
ers: L15832 (light chain, nps 15838–15858) and H408
(heavy chain nps 408–429). The results of the amplifica-
tion were then purified using ExoSAP-IT®  technology.
Finally, starting from position 16050, at least 725 pb of
the mitochondrial DNA control region were double-
strand sequenced using an ABI Prism BigDye Terminator
Cycle Sequencing Ready Reaction Kit (Perkin Elmer®). The
same primers were used for amplification and sequencing,
L15832 and H408, together with 2 additional primers:
L16200 (light chain, nps 16194–16217) and H263
(heavy chain nps 263–285). Each individual was also
tested for the presence of a polymorphism in position
7028 by digestion with the AluI enzyme of an amplicon
obtained with primers L6909 (light chain, nps 6890–
6909) and H7115 (heavy chain nps 7115–7131).
The analysis made it possible to identify each individual's
haplotype and haplogroup markers. The individuals' hap-
logroup affiliation were determined on the basis of recent
studies involving total sequencing of mitochondrial DNA
[10-13]. Affiliations to the main European haplogroups
were confirmed by standard RFLP tests (UK:12308HinfI;JT
4216NlaIII; J: 13704Bsto1; T: 15606AluI; H7025AluI V
4577NlaIII) on diagnostic positions for the haplogroups
on the mtDNA coding segment [14,15].
Control Population and Statistics
The distribution of carriers of mutation on OPA1 gene
among the haplogroups was compared with frequencies
observed in a sample of the French population consisting
of 1385 individuals [8]. Each haplogroup was tested as a
possible risk factor for developing the pathology against
the rest of the population. In turn statistical comparisons
were carried out on the largest cluster, using standard "Khi
2" methods without correction; the haplogroup and sub
haplogroup were tested by fisher's exact test. The relative
risk estimated for each haplogroup was defined by the
"odds ratio" method, with a confidence interval calcu-
lated by the Miettinen method [16].
Results
MtDNA sequencing D-loop and RFLP analysis of the cod-
ing segment revealed 37 different haplotypes, among theBMC Medical Genetics 2009, 10:70 http://www.biomedcentral.com/1471-2350/10/70
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Table 1: RFLP and Control-Region mtDNA Haplotypes from the French OPA1 mutation carrier
patient super haplogroup haplogroup POLYMORPHISM OBSERVED BETWEEN POSITION 16050–
16569 AND 1–205
RFLP
1421 R0 H 16519T>C, 195T>C -7025AluI
1043 R0 H 16519T>C, 146T>C -7025AluI
1659 R0 H 16519T>C -7025AluI
1148 R0 H 16519T>C -7025AluI
1284 R0 H 16311T>C, 16519T>C -7025AluI
1090 R0 H 16235A>G, 16291C>T, 16293A>G, 16400C>T -7025AluI
1428 R0 H 16189T>C, 16194-del, 16519T>C -7025AluI
1568 R0 H 16188C>T, 16295C>T, 16519T>C, 150C>T -7025AluI
1344 R0 H 16188C>G, 16189T>C, 16264C>T, 16311T>C, 16519T>C -7025AluI
1267 R0 H 16129G>A, 16264C>T, 16316A>G, 16519T>C, 195T>C -7025AluI
1366 R0 H 16086T>C, 16189T>C,16519 T>C -7025AluI
1091 R0 H1a 16162A>G, 16274G>A, 16519T>C, 73A>G -7025AluI
1163 R0 H1b 16183A>C, 16189T>C, 16291C>T, 16356T>C, 16519T>C, 
152T>C
-7025AluI
1531 R0 H5 16184C>T, 16304T>C, 16519T>C -7025AluI
1686 R0 H5 16243T>C, 16304T>C, 152T>C -7025AluI
1505 R0 H5 16304T>C, 16519T>C, 146T>C -7025AluI
1054 R0 H11 16293A>G, 16519T>C -7025AluI
1032 R0 preV (HV0) 16298T>C, 72T>C +4577NlaIII, +7025AluI
1620 R0 V (HV0) 16298T>C, 72T>C, 195T>C, 198C>T +4577NlaIII, +7025AluI
1697 R0 V (HV0) 16298T>C, 16311T>C, 72T>C, 195T>C -4577NlaIII, +7025AluI
1332 JT J 16069C>T, 16126T>C, 73A>G, 185G>A +4216NlaIII; -13704BstOI,+7025AluI
1743 JT J 16069C>T, 16126T>C, 73A>G, 185G>A +4216NlaIII; -13704BstOI,+7025AluI
1779 JT J 16069C>T, 16126T>C, 73A>G, 185G>A +4216NlaIII; -13704BstOI,+7025AluI
1464 JT T 16126T>C, 16153G>A, 16294C>T, 16519T>C, 41C>T, 73A>G, 
150C>T, 200A>G
+4216NlaIII;+13704BstOI,+7025AluI
1099 JT T1 16126T>C, 16163A>G, 16186C>T, 16189T>C, 16294C>T, 
16519T>C, 73A>G, 152T>C, 195T>C
+4216NlaIII;+13704BstOI,+7025AluI
1763 JT T2 16126T>C, 16294C>T, 16296C>T, 16304T>C, 16519T>C, 
73A>G, 195T>C
+4216NlaIII;+13704BstOI,+7025AluIBMC Medical Genetics 2009, 10:70 http://www.biomedcentral.com/1471-2350/10/70
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41 carriers of a mutation on OPA1 (table 1). The range of
haplogroups was extremely wide and included the typi-
cally European haplogroups H, preV, V, J, T1, T2, K, U2,
U5, U4, X, and W, plus two representatives each of African
haplogroup U6, and Asian haplogroup D (figure 1). The
presence of the two last haplogroups is expected, since
African mtDNAs are common in France and members of
Asian super-haplogroup M are sporadically identified in
Europe.
In light of these results (table 1), we investigated whether
there was a difference in distribution among haplogroups
of the patient population carrying mutation on OPA1
compared to the reference population. We therefore com-
pared the distribution of 41 mutation carriers among
European haplogroups with the frequencies obtained for
1385 unrelated French people [8]. The patients were dis-
tributed on a phylogenetic tree of the European popula-
tion based on recent total sequencing studies of
mitochondrial DNA [10-13]. This tree shows the main
haplogroups found in the French population. We used the
new haplogroup nomenclature recently proposed [17] to
place our patients on this tree, indicating the number of
individuals per haplogroup (figure 1).
For the purposes of statistical comparison, we collected
individuals in phylogenetic clusters centered on super-
haplogroup R. This point was chosen as it corresponded
to the node where the R line, which represents over 90%
of the French population, divides off from the rest of the
human phylogeny. We then analyzed whether each clus-
ter constituted a risk factor compared to the rest of the
population, using the odds ratio method, with Khi2 to test
significance (table 2). We tested the 3 largest clusters rep-
resentative of a phylogenic reality, so that we could use
Khi2 without correction. The statistic analyses of the larg-
1348 U U3 16343A>G, 16390G>A, 16519T>C, 73A>G, 150C>T -12308HinfI,+7025AluI
1106 U U4 16111C>T, 16140T>C, 16356T>C, 16362T>C, 16519T>C, 
73A>G, 146T>C, 152T>C, 195T>C
-12308HinfI,+7025AluI
1291 U U5 16192C>T, 16256C>T, 16270C>T, 16291C>T, 16399A>G, 
16519T>C, 73A>G
-12308HinfI,+7025AluI
1742 U U5 or U4 16270C>T, 16356T>C, 16519T>C, 73A>G, 152T>C, 195T>C -12308HinfI,+7025AluI
1363 U U6 16172T>C, 16219A>G, 16261C>T, 16311T>C, 16361G>A, 
73A>G
-12308HinfI,+7025AluI
1278 U K 16093T>C, 16224T>C, 16311T>C, 16519T>C, 73A>G -12308HinfI,+7025AluI
1455 U K 16093T>C, 16224T>C, 16311T>C, 16519T>C, 73A>G -12308HinfI,+7025AluI
1587 U K 16064T>K, 16129G>A, 16224T>C, 16311T>C, 16519T>C, 
73A>G, 180T>Y
-12308HinfI,+7025AluI
1799 U K 16224T>C, 16311T>C, 16519T>C, 73A>G, 146T>C, 152T>C -12308HinfI,+7025AluI
1887 U K 16213G>A, 16224T>C, 16311T>C, 16519T>C, 73A>G, 
146T>C
-12308HinfI,+7025AluI
1426 other D (M) 16260C>T, 16261C>T, 16266C>T, 16301C>T, 16311T>C, 
16319G>A, 16362T>C, 16527C>T, 64C>T, 73A>G, 195T>C
+7025AluI
1358 other W 16083C>T, 16223C>T, 16292C>T, 16519T>C, 73A>G, 
106G>A, 189A>G, 195T>C, 204T>C
+7025AluI
1588 other W 16192C>T, 16223C>T, 16292C>T, 16325T>C, 16519T>C, 
73A>G, 189A>G, 194C>T, 195T>C, 204T>C
+7025AluI
1759 other X 16189T>C, 16194delA, 16223C>T, 16278C>T, 16519T>C, 
73A>G, 153A>G, 195T>C
+7025AluI
1512 other X 16189T>C, 16192C>T, 16223C>T, 16278C>T, 16519T>C, 
73A>G, 153A>G, 195T>C
+7025AluI
Table 1: RFLP and Control-Region mtDNA Haplotypes from the French OPA1 mutation carrier (Continued)BMC Medical Genetics 2009, 10:70 http://www.biomedcentral.com/1471-2350/10/70
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Phylogenical repartition of the 41 OPA1 mutation carriers Figure 1
Phylogenical repartition of the 41 OPA1 mutation carriers. The phylogenic tree was based on recent total sequencing 
studies of mitochondrial DNA [11,12]; the new haplogroup nomenclature is used[17]. The different polymorphisms used for 
haplogroup determination in this study are indicated in blue. The Red Cross indicate the number of individuals per haplogroup.
Table 2: Relative risk estimated of each haplogroup to develop the OPA1 pathology against the rest of the population
OPA1 French p-value 1 O.R p-value 2 lower 95% CI Upper 95% CI
carriers Population Fisher Khi2
R0 20 726 0,75 0,86 0,65 0,46 1,61
>H 17 660 0.52
>HV0 3 66 0.44
U 10 303 0.70 1,15 0,70 0,56 2,38
>U5 2 115 0.57
>K 5 107 0.24
JT 6 224 0.89 0,89 0,79 0,37 2,14
>J 3 106 0.95
>T 3 118 0,86
N5 1 3 2 0 , 5 8BMC Medical Genetics 2009, 10:70 http://www.biomedcentral.com/1471-2350/10/70
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est clusters fail to show statistical differences (p > 0.58).
To obtain more detailed results, we applied the fisher's
exact test to the largest sub-cluster of R0 i.e. haplogroups
H and haplogroup HV0. The frequency of haplogroup H
and HV0 did not seem significantly different from that
observed in the control population (p  0.44). In view of
the lack of data on the proportions of H sub-haplogroups
in the French population, as well as the considerable var-
iation in the frequency of sub-haplogroups in Western
Europe [11], we have decided not to subdivide this haplo-
group. As in the case of haplogroup R0, we tested for sig-
nificant differences in the sub-cluster of UK and JT
haplogroups, however, there was no significant difference
for the sub-cluster (p  0.24).
Discussion
The mitochondrial genetic background is known to influ-
ence the expression of the optic atrophy: i.e the LHON
mitochondrial primary mutations G11778A and
T14484C showed significant clustering on Caucasian
mtDNA haplogroup J. It has been suggested that this clus-
tering result from an accumulation of non-synonymous J
polymorphisms on the cytochrome b gene G15257A,
T14798C [18]. Indeed these polymorphisms could affect
the complex III efficiency and more specifically the Coen-
zyme Q binding sites, thus upsetting the proton pump Q
cycle and, finally, oxidative phosphorylation (OXPHOS)
coupling [19,20]. Consequently J polymorphisms could
amplify the effect of the G11778A and T14484C muta-
tions on the biochemical and phenotypical levels (figure
2). A recent study, based on a large cohort of relative
patients confirm that the risk of visual failure is greater
when the mutations are present in specific subgroups of
haplogroup J [21]. However, we could not exclude that
the association of the T14484C mutation with haplo-
group J might be the result of an elevated specific muta-
tion rate as proposed by [22].
In order to test the influence of the mitochondrial genetic
background on the expression of the mutation of the
OPA1 gene, we compared the distribution of 41 French
patients among European haplogroups with a French
Influence of mtDNA background on the differentoptic atrophy forms Figure 2
Influence of mtDNA background on the differentoptic atrophy forms. The influence of the mtDNA background (i.e., 
Haplogroup J) may vary according to deleterious effect of a mutation on mitochondrial oxidative phosphorylation. For exam-
ple, "mild" mutations (i.e., T14484C and G11778A) could have to be amplified by the additional negative effect of mtDNA 
background (i.e., G15257A, T14798C) to influence the disease expression; where as "severe mutation" (i.e., G3460A, OPA1) 
does not necessarily need. The dashed spears describe unclear or unproved relations.
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population sample constituted of 1385 individuals and
described by a recent study [8]. The distribution of the
patient population revealed no significant difference com-
pared to the French population.
Interestingly, the clinical expression of the G3460A
mtDNA mutation which is also responsible for LHON
[23] is not influenced by mtDNA haplogroup J [24-27].
This mutations has a stronger deleterious effect on mito-
chondrial oxidative phosphorylation (OXPHOS) with a
decrease of 60–80% electron transport activity [28]. In
contrast, the LHON primary mutations influenced by
haplogroup J (T14484C and G11778A) only display a
decrease of 0–25% electron transport activity[28]. It is
tempting to speculate that the deleterious effect of these
later "mild" mutations could have to be amplified by the
additional negative effect of mtDNA background to influ-
ence the disease expression.
The absence of strong influence of mtDNA background on
OPA1-related ADOA expression suggests that, similarly to
G3460A mtDNA mutation, the deleterious effect of OPA1
mutations could be responsible itself of the pathology
and do not need additional mitochondrial factor. Interest-
ingly, although the main function of OPA1 is devoted to
mitochondrial inner membrane remodeling, recent data
suggest that mutations of OPA1 could have strong delete-
rious effect on oxidative phosphorylation efficiency
[29,30]. It is tempting to speculate that this energetic
defect could be sufficient to induce clinical expression
independently to the mtDNA background. Interestingly it
has been proposed by Han et al. that the expression of
OPA1-negative ADOA could remain dependant of addi-
tional negative effect of mtDNA background [7]. How-
ever, his study was based on an insufficient number of
patients and the patients may have a heterogeneous
genetic basis, given that multiple loci associated with
DOA still await for other genes to be discovered.
Conclusion
These data allow to conclude that OPA1 should be consid-
ered as a "severe mutation", directly responsible of the
optic atrophy, whereas OPA1-negative ADOA mutations
need an external parameter to express the pathology (i.e.
synergistic interaction with mitochondrial background).
However, if the influence of mitochondrial background
should be excluded for OPA1 mutation, other external
parameters as well as environmental or nuclear factors
could be implied in the phenotypic expression of the
pathology. Although a large study remains to be per-
formed to investigate the possible influences of mtDNA
haplogroups on clinical phenotypes of OPA1-related
ADOA (ie age of onset, progressivity of the disease, addi-
tional neurological symptoms such as neurosensorial
deafness), our result indicates the absence of major influ-
ence of mtDNA haplogoups in the basic penetrance of the
disease. In an attempt to try to better explain the interac-
tions between mitochondrial energetic defect and heredi-
tary optic neuropathies, we propose a model, presented in
figure 2, that summarize the influence of mtDNA in optic
atrophies.
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